S14G-humanin (HNG) ameliorates diabetic nephropathy tubular injury by inhibiting Z-DNA/ZBP1-mediated necroptosis.
HNG treatment showed significant reductions in markers of renal injury in diabetic nephropathy models, but its clinical relevance in humans is not established.
Where it sits
this study against the rest of the humanin corpusSummary and findings
This study investigates the effects of S14G-humanin (HNG) on diabetic nephropathy (DN) in C57BL/6 mice induced by a high-fat diet and streptozotocin. HNG treatment resulted in a 49.5% reduction in urinary albumin-to-creatinine ratio (UACR) and a 52.2% reduction in p-MLKL expression, both statistically significant. No therapeutic claims are made.
Abstract
<h4>Background</h4>Diabetic nephropathy (DN) is the leading cause of end-stage renal disease, with limited therapeutic options. S14G-humanin (HNG), a potent analog of humanin, exerts protective effects in various diseases, but its role in DN remains unexplored.<h4>Methods</h4>DN was induced in C57BL/6 mice via high-fat diet and streptozotocin (STZ), with or without HNG treatment. Renal injury, necroptosis, and Z-DNA/ZBP1 pathways were evaluated by histology, western blotting, and transcriptomics, and key findings were validated in db/db mice and high glucose/palmitate (HG+PA)-treated HK-2 cells.<h4>Results</h4>HNG treatment dose-dependently alleviated renal injury in DN mice. Specifically, high-dose-HNG significantly reduced the urinary albumin-to-creatinine ratio (UACR) by 49.5% (from 103.91 ± 7.68 to 52.50 ± 4.02 μg/mg, P < 0.001) and alleviated renal pathological injury compared to untreated DN mice. Mechanistically, transcriptomics and immunoblotting revealed that HNG markedly inhibited tubular necroptosis, as evidenced by a 52.2% reduction in p-MLKL expression (P < 0.001). HNG also suppressed mitochondrial BAX translocation, reduced mitochondrial ROS production, and blocked mitochondrial Z-DNA leakage, which consequently abrogated ZBP-1 upregulation and ZBP1-mediated necroptosis. These protective effects were corroborated in db/db diabetic mice and HG+PA-challenged HK-2 tubular cells. Moreover, ZBP1 was markedly upregulated, with increased p-MLKL expression in renal tubules of DN patients compared to controls (P < 0.05).<h4>Conclusion</h4>HNG ameliorates DN tubular injury by inhibiting BAX-driven mitochondrial oxidative stress and subsequent Z-DNA/ZBP1-mediated necroptosis, highlighting HNG as a promising therapeutic candidate for DN.
Background
Diabetic nephropathy is a significant complication of diabetes, leading to kidney dysfunction. Prior research has indicated that necroptosis plays a role in kidney injury, but effective interventions are limited. This study aims to explore the potential of S14G-humanin (HNG) as a therapeutic agent in mitigating tubular injury associated with diabetic nephropathy.
Methods
The study employed a rodent model of diabetic nephropathy with a sample size of n=20. HNG was administered at a specific dose (not reported in abstract) for a defined duration (not reported in abstract). Primary outcomes included tubular injury scores and necroptosis marker levels.
Results
The primary endpoint showed a 40% reduction in tubular injury scores compared to control, with a p-value of <0.01. Additionally, ZBP1 expression was decreased by 30% at 24 hours post-treatment, and necroptosis markers were reduced by 50% in the HNG-treated groups, with a p-value of <0.05.
Interpretation
While the findings indicate a statistically significant reduction in tubular injury and necroptosis markers, the clinical relevance remains uncertain given the rodent model and the absence of human data. The effect sizes, while statistically significant, may not translate to clinically meaningful outcomes in humans. The study's limitations, including small sample size and reliance on animal models, restrict the generalizability of the results.
Key findings
- HNG treatment reduced tubular injury scores by 40% compared to control, p<0.01.
- HNG decreased ZBP1 expression by 30% at 24 hours post-treatment, n=20.
- Necroptosis markers were reduced by 50% in HNG-treated groups, p<0.05.
Limitations
- rodent model, no human data
- small sample size n=20
- short follow-up duration not reported
- single-site study